Personalized and Precision Medicine Journal
Where Innovations Meets Personalized and Precision Medicine

Pituitary hormones Profile, Cholesterol Levels, and Steroidogenic Genes Xxpression are Useful Information in Prostate Cancer

Document Type : Original Article

Authors

Ghasem Ghorbani Vale Zaghard 1
Mehdi Haghi 2
Mehdi Ghiamirad 3
Saeid Ghorbian 1
Mehdi Ebrahimi 4

1 Department of Molecular Genetics, Ahar Branch, Islamic Azad University, Ahar, Iran.

2 Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.

3 Department biology, faculty of Basic Sciences, Islamic Azad university Ahar branch, Ahar, Iran.

4 Department of Biochemistry and Biophysics, Faculty Of Biology Science, Varamin-Pishva branch, Islamic Azad University, Varamin, Iran.

https://doi.org/10.22034/ppmj.2026.735667
Abstract
Objective: To investigate the relationship between changes in the level of Pituitary hormones, cholesterol levels, and the expression of genes involved in the biosynthesis of androgens, this study was designed.
Methods: In this study, the amount of changes in the levels of LH, FSH, and PRL hormones, as well as the level of cholesterol as a precursor of androgens, LDL and HDL lipoproteins, and the expression level of two genes, CYP17A1 and CYP11A1, in 120 people with prostate cancer as a case group and 120 people with BPH as a control group by RT-qPCR.
Results: The statistical analysis demonstrated that serum levels of testosterone, LH, and TSH were significantly higher in the malignant group compared to the benign group. PRL levels were also elevated in the Prostate cancer (PCa) group; however, this difference did not reach statistical significance. No significant difference was observed in serum PSA levels between the two groups. Prostate volume was significantly greater in the benign group than in the malignant group. Serum cholesterol levels were significantly higher in the PCa group compared to the Benign prostatic hyperplasia (BPH) group. In contrast, serum levels of LDL and HDL lipoproteins showed no significant differences between the groups. Additionally, the expression levels of CYP11A1 and CYP17A1 genes were significantly increased in the PCa group relative to the BPH group.
Conclusion: The results of this study showed that monitoring the hormonal profile and cholesterol level can play an important role in predicting the course of the disease.

Keywords

Prostate Cancer
Androgens
Testosterone
Cholesterol
Pituitary Hormones
1.    Pilleron S, Sarfati D, Janssen‐Heijnen M, Vignat J, Ferlay J, Bray F, Soerjomataram I. Global cancer incidence in older adults, 2012 and 2035: a population‐based study. International journal of cancer. 2019 Jan 1;144(1):49-58.
2.    Park HJ, Won JE, Sorsaburu S, Rivera PD, Lee SW. Urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: a systematic review focusing on tadalafil. The world journal of men’s health. 2013 Dec 1;31(3):193-207.
3.    De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB, Nelson WG. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. Journal of cellular biochemistry. 2004 Feb 15;91(3):459-77.
4.    De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, Sciarra A, Tubaro A. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. European urology. 2011 Jul 1;60(1):106-17.
5.    Cabarkapa S, Perera M, McGrath S, Lawrentschuk N. Prostate cancer screening with prostate-specific antigen: A guide to the guidelines. Prostate international. 2016 Dec 1;4(4):125-9.
6.    Perdana NR, Mochtar CA, Umbas R, Hamid AR. The risk factors of prostate cancer and its prevention: a literature review. Acta medica indonesiana. 2017 May 10;48(3):228-38.
7.    Isharwal S, Modi S, Arora N, Uhlrich III C, Giri B, Barlass U, Soubra A, Chugh R, Dehm SM, Dudeja V, Saluja A. Minnelide inhibits androgen dependent, castration resistant prostate cancer growth by decreasing expression of androgen receptor full length and splice variants. The Prostate. 2017 May;77(6):584-96.
8.    Gonthier K, Poluri RT, Audet-Walsh E. Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology. 2019 Jul 1;191:105367.
9.    Cole TJ, Short KL, Hooper SB. The science of steroids. InSeminars in Fetal and Neonatal Medicine 2019 Jun 1 (Vol. 24, No. 3, pp. 170-175). WB Saunders.
10.Fujita K, Nonomura N. Role of androgen receptor in prostate cancer: a review. The world journal of men’s health. 2019 Sep 1;37(3):288-95.
11.Sorić T, Vidić I. Is Testosterone Prognostic in Prostate Cancer Treatment? The Urological Standpoint. Acta Clinica Croatica. 2019 Nov 1;58(Supplement 2):64-8.
12.Kinter KJ, Anekar AA. Biochemistry, Dihydrotestosterone. [Updated 2023 Mar 6 Treasure Island (FL): StatPearls Publishing; 2023 Jan.
13.Zhou J, Wang Y, Wu D, Wang S, Chen Z, Xiang S, Chan FL. Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer. Oncogene. 2021 Apr 15;40(15):2625-34.
14.Kong Y, Cheng L, Mao F, Zhang Z, Zhang Y, Farah E, Bosler J, Bai Y, Ahmad N, Kuang S, Li L. Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC). Journal of Biological Chemistry. 2018 Sep 1;293(37):14328-41.
15.Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, Neumann RD, Nelson CC, Guns ES, Wasan KM. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration‐resistant prostate cancer in a mouse xenograft model. The Prostate. 2010 Mar 1;70(4):390-400.
16.Huhtaniemi R, Oksala R, Knuuttila M, Mehmood A, Aho E, Laajala TD, Nicorici D, Aittokallio T, Laiho A, Elo L, Ohlsson C. Adrenals contribute to growth of castration-resistant VCaP prostate cancer xenografts. The American journal of pathology. 2018 Dec 1;188(12):2890-901.
17.Stuchbery R, McCoy PJ, Hovens CM, Corcoran NM. Androgen synthesis in prostate cancer: do all roads lead to Rome?. Nature Reviews Urology. 2017 Jan;14(1):49-58.
18.Shiraishi K, Matsuyama H. Gonadotoropin actions on spermatogenesis and hormonal therapies for spermatogenic disorders. Endocrine journal. 2017;64(2):123-31.
19.Polotti CF, Kim CJ, Chuchvara N, Polotti AB, Singer EA, Elsamra S. Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics. Expert Opinion on Drug Metabolism & Toxicology. 2017 Dec 2;13(12):1265-73.
20.Zirkin BR, Papadopoulos V. Leydig cells: formation, function, and regulation. Biology of reproduction. 2018 Jul 1;99(1):101-11.
21.Li L, Papadopoulos V. Advances in stem cell research for the treatment of primary hypogonadism. Nature Reviews Urology. 2021 Aug;18(8):487-507.
22.David MK, Leslie SW. Prostate Specific Antigen. [Updated 2022 Nov 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-.
23.Stattin P, Lumme S, Tenkanen L, Alfthan H, Jellum E, Hallmans G, Thoresen S, Hakulinen T, Luostarinen T, Lehtinen M, Dillner J. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. International journal of cancer. 2004 Jan 20;108(3):418-24.
24.Carruba G. Estrogen and prostate cancer: An eclipsed truth in an androgen‐dominated scenario. Journal of cellular biochemistry. 2007 Nov 1;102(4):899-911.
25.Paunikar VM, Barapatre SA. Relationship between endogenous testosterone and prostate carcinoma. Journal of Family Medicine and Primary Care. 2022 Jul;11(7):3735.
26.Rivas AM, Mulkey Z, Lado-Abeal J, Yarbrough S. Diagnosing and managing low serum testosterone. Proc (Bayl Univ Med Cent). 2014 Oct;27(4):321-4. doi: 10.1080/08998280.2014.11929145. PMID: 25484498; PMCID: PMC4255853.
27.Tafuri A, Sebben M, Shakir A, Pirozzi M, Processali T, Rizzetto R, Amigoni N, Brunelli M, Migliorini F, Siracusano S, Cerruto MA. Endogenous testosterone mirrors prostate cancer aggressiveness: correlation between basal testosterone serum levels and prostate cancer European Urology Association clinical risk classes in a large cohort of Caucasian patients. International Urology and Nephrology. 2020 Jul;52:1261-9.
28.Datrianto DS, Budipitojo T, Prihatno SA. Secretome improves testosterone and androgen-binding protein production in testicular dysfunction rats induced by cisplatin. Journal of Advanced Veterinary and Animal Research. 2021 Dec;8(4):687.
29.Rizzuti A, Stocker G, Santos HO. Exploring the role of testosterone replacement therapy in benign prostatic hyperplasia and prostate cancer: a review of safety. Uro. 2022 Feb 11;2(1):30-9.
30.Oduwole OO, Poliandri A, Okolo A, Rawson P, Doroszko M, Chrusciel M, Rahman NA, Serrano de Almeida G, Bevan CL, Koechling W, Huhtaniemi IT. Follicle‐stimulating hormone promotes growth of human prostate cancer cell line‐derived tumor xenografts. The FASEB Journal. 2021 Apr;35(4):e21464.
31.Hamid AR, Kusuma Putra HW, Sari NP, Diana P, Sesari SS, Novita E, Gultom FL, Saraswati M, Tanurahardja B, Umbas R, Mochtar CA. Early upregulation of AR and steroidogenesis enzyme expression after 3 months of androgen-deprivation therapy. BMC urology. 2020 Dec;20(1):1-0.
32.Harper I. Prostate Cancer and Environmental Exposure to Trace Elements in Different Ethnic Groups. International Journal of Collaborative Research on Internal Medicine & Public Health. 2022;14(4):1-2.
33.Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, Garrels K, Hotte S, Kattan MW, Raghavan D, Saad F. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. Journal of Clinical Oncology. 2014 Oct 10;32(30):3436.
34.Goffin V, Hoang DT, Bogorad RL, Nevalainen MT. Prolactin regulation of the prostate gland: a female player in a male game. Natu
35.Raftopulos NL, Washaya TC, Niederprüm A, Egert A, Hakeem-Sanni MF, Varney B, Aishah A, Georgieva ML, Olsson E, Dos Santos DZ, Nassar ZD. Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover. Cancer & metabolism. 2022 Dec;10(1):1-5.
36.Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, Neumann RD, Nelson CC, Guns ES, Wasan KM. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration‐resistant prostate cancer in a mouse xenograft model. The Prostate. 2010 Mar 1;70(4):390-400.
37.Zaghard GG, Haghi M, Ghiamirad M, Ghorbian S, Ebrahimi M. Expression of HSD3B1 and HSD3B2 Genes in Adenocarcinoma and Benign Prostatic Hyperplasia. Gene, Cell and Tissue. 2023 Jan 31;10(1).
Personalized and Precision Medicine Journal
Volume 11, Issue 40 - Serial Number 40
Original article
Winter 2026
Pages 8-15

  • Receive Date 13 November 2025
  • Revise Date 26 January 2026
  • Accept Date 28 February 2026

Home

Publication Ethics

Guide for Authors

Submit Manuscript

Contact Us